Global Endometriosis Market Report 2018: Insights, Epidemiology and Forecasts to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Endometriosis - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

According to research, the global market [that includes 7MM, Rest of Europe (RoE) and Rest of World (RoW)] of Endometriosis was USD 1,856 Million in 2016, and is expected to increase at a significant growth during the study period i.e., 2016-2027.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Endometriosis from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

According to research, the prevalent cases of Endometriosis in 7 major markets was 13.8 Million in 2016 and, is expected to increase at a significant growth rate during the study period i.e., 2016-2027. Among 7MM United States account for highest incident population of Endometriosis i.e., 7.4 Million followed by United Kingdom.

The marketed drugs available for the treatment of Endometriosis mainly include Lupron (Abbvie), Visanne/Dienogest (Bayer Healthcare), Zoladex (AstraZeneca), Synarel (Pfizer) and Depo-SubQ. Detailed chapters for all of these drugs, along with the promising upcoming therapies such as Elagolix (Abbvie), Femitra (Endooceutics) etc. have been covered in the report.

Companies Mentioned

  • AbbVie Inc
  • Bayer HealthCare Pharmaceuticals
  • EndoCeutics Inc

Key Topics Covered:

1. Report Introduction

2. Endometriosis Market Overview at a Glance

3. Disease Background and Overview: Endometriosis

4. Epidemiology of Endometriosis in 7MM

5. Treatment Algorithm

6. Current Unmet Needs

7. Marketed Drugs

8. Emerging Therapies

9. Global Endometriosis: Country-Wise Market Analysis

10. Market Drivers

11. Market Barriers

12. Appendix

13. Report Methodology

14. Capabilities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/985qgn/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Sexual and Reproductive Health Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Sexual and Reproductive Health Drugs